NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
This article was originally published in The Tan Sheet
Executive Summary
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing